Imfinzi plus tarlatamab shows survival gains in lung cancer trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-sta
September 8, 2026 9:00 AM EDTIMFINZI is the first and only immunotherapy in combination with a bispecific T-cell engager to show survival benefit in this setting
DeLLphi-305 Phase III trial results reinforce IMFINZI as the backbone immunotherapy for small cell lung cancer across stages of disease
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgens tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus IMFINZI alone as a 1st-line... More
